Lannett Company Inc (NYSE:LCI) reported on Monday the availability of Cediprof Inc's US FDA approved levothyroxine Sodium Tablets USP under an interim exclusive supply and distribution agreement.
According to the companies, levothyroxine is a manufactured form of the thyroid hormone thyroxine. It is used to treat thyroid hormone deficiency, including the severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors.
Following two separate legal challenges by Cediprof's previous distributor of levothyroxine Sodium Tablets, the rulings now allows Lannett to commence distributing the procduct in the US.
Cediprof Inc is a part of the Neolpharma Pharmaceutical Group, which engages in the research, development, production and distribution of generic medicines in the following therapeutic areas: CNS, oncology, metabolic disease, rheumatology and infectious diseases.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886